Diabetes Discourse

Host: John Buse, MD, PhD Guest: David Simmons, MD Gestational hypertension is more common in preeclampsia, and there’s more chance of the baby ending up in the neonatal intensive care unit. So what can we learn from the randomized trials of women patients with gestational diabetes? Learn more with Dr. John Buse as he speaks with Dr. David Simmons, Distinguished Professor of Medicine at the Western...

Host: John Buse, MD, PhD Guest: Karen D. Corbin, PhD, RD One of the biggest missing links in current literature about obesity and the gut microbiome was causality. In an effort to address that gap, a recent clinical trial was conducted, and now, the results are in. So what were the key findings, and how can we translate those findings into clinical practice? Find out how one’s diet can affect the...

Host: John Buse, MD, PhD Guest: Anna Kahkoska, MD, PhD Continuous glucose monitoring (CGM) can help improve glycemic management in patients with type 1 diabetes (T1D), but integrating this technology can be a complex learning process for older adults. So what do we need to consider when it comes to CGM use in older adults? Find out with Dr. John Buse and Dr. Anna Kahkoska, Assistant Professor in t...

Host: John Buse, MD, PhD Guest: Anastassios Pittas, MD, MS Vitamin D has numerous benefits, and according to a recent study, it can even help reduce the risk of type 2 diabetes in patients with prediabtes. Learn more about the key findings from this research with Dr. John Buse and Dr. Anastassios Pittas, Professor of Medicine and Chief of Endocrinology at Tufts Medical Center.

Host: John Buse, MD, PhD Guest: Viral Shah, MD Severe hypoglycemia can lead to dangerous challenges, one of them being an increase in vehicular accidents. Dive into the results from a study that investigated the correlation between the prevalence of hypoglycemia while driving in adults with type 1 diabetes (T1D) and how many of those cases might have led to vehicular accidents with Dr. John Buse a...

Host: John Buse, MD, PhD Guest: Steven Nissen, MD Among statin-intolerant patients, treatment with bempedoic acid is associated with a lower risk of major adverse cardiovascular events according to a recent study. Dive into the study’s key findings with Dr. John Buse and Dr. Steven Nissen, who published the placebo-controlled study of bempedoic acid among statin-intolerant patients in The New Engl...

Host: John Buse, MD, PhD Guest: Elizabeth Selvin, PhD, MPH As obesity rates continue to rise in adults with type 1 diabetes, what can we do to combat this growing obstacle? Dr. John Buse speaks with an expert in the field, Dr. Elizabeth Selvin, about obesity in patients with type 1 diabetes and shares management strategies.

Host: John Buse, MD, PhD Guest: Ania Jastreboff, MD, PhD Counseling patients with obesity who are on GLP-1 receptor agonists can be challenging. How can we leverage the biology of GLP-1 receptor antagonists to improve weight loss while avoiding side effects? Dr. John Buse speaks with a leading expert in the field, Dr. Ania Jastreboff, about the role of GLP-1 receptor agonists in weight loss.

Host: John Buse, MD, PhD Guest: Jennifer B. Green, MD The COORDINATE Study evaluated patients with cardiovascular disease and type 2 diabetes who encounter barriers in receiving newer diabetes medications. To better understand these gaps in care, Dr. John Buse speaks with one of the researchers, Dr. Jennifer Green from Duke University in Durham, North Carolina.

Host: John Buse, MD, PhD Guest: Abbie E. Smith-Ryan, PhD, CSCS*D, FNSCA There are immeasurable benefits to exercise, but the hard part for patients may be getting started. How can we help our patients make exercise a part of their lives? Dr. John Buse speaks with Dr. Abbie Smith-Ryan, a Professor of Exercise Physiology at the University of North Carolina – Chapel Hill, about the key benefits of ex...

Host: John Buse, MD, PhD Guest: Sue Pedersen, MD, FRCPC New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.

Host: John Buse, MD, PhD Guest: Silva Arslanian, MD New research on once-daily semaglutide for adolescent patients with obesity may alter clinicians’ approach to care. What do we need to know? Dr. John Buse speaks with one of the study’s investigators, Dr. Silva Arslanian, from the University of Pittsburgh to dive into this clinical data and explore how these results may change the treatment lands...

Host: John Buse, MD, PhD Guest: Jennifer B. Green, MD What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study’s investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about...

Host: John Buse, MD, PhD Guest: Deborah Wexler, MD The GRADE study demonstrated the efficacy of different treatment options for patients with type 2 diabetes. To learn more about these treatment options, Dr. John Buse joins one of the study’s investigators, Dr. Deborah Wexler from Harvard Medical School and the Massachusetts General Hospital Diabetes Center, to dive into this study.

Host: John Buse, MD, PhD Guest: Steven Russell, MD, PhD Research continues to emerge on the bionic pancreas and its capabilities, and a recent study shows how it can count carbohydrates and lower A1c for patients with type 1 diabetes. To find out how it does, Dr. John Buse is joined by Dr. Steven Russell, an Associate Professor of Medicine at Harvard Medical School at the Massachusetts General Hos...

Host: John Buse, MD, PhD Guest: Martin de Bock, PhD FRACP Recent research has explored the efficacy of open source automated insulin delivery devices for patient with type 1 diabetes. What did these results tell us? Dr. John Buse speaks with Dr. Martin de Bock, a pediatric endocrinologist at the University of Otago in Christchurch, New Zealand, to dive deeper into this research.

Host: John Buse, MD, PhD Guest: Matthew Crowley, MD Can telehealth change the way we manage persistently controlled type 2 diabetes (PPDM)? Dr. John Buse speaks with Dr. Matt Crowley, an Associate Professor of Medicine in the Department of Medicine in the Division of Endocrinology, Metabolism and Nutrition at Duke University, to explore some of the research on different methods of telehealth.

Host: John Buse, MD, PhD Guest: Seth Berkowitz, MD, MPH Food assistance programs like the Supplemental Nutrition Assistance Program (SNAP) can help relieve food insecurity. But can they also lower healthcare spending? To answer this question, Dr. John Buse sits down with Dr. Seth Berkowitz from the Division of General Medicine and Clinical Epidemiology at the University of North Carolina School of...

Host: John Buse, MD, PhD Guest: Ashok Balasubramanyam, MD Researchers from the GRADE study zeroed in on islet autoimmunity in beta cell dysfunction for patients with type 2 diabetes. What did various treatment options show us? Dr. John Buse speaks with Dr. Ashok Balasubramanyam, a Professor in the Department of Endocrinology, Diabetes and Metabolism at Baylor College of Medicine.

Host: John Buse, MD, PhD Guest: Jose C. Florez, MD, PhD Precision medicine may be the future of diabetes treatment. But what’s needed to implement this approach into practice? Here to explore this concept with Dr. John Buse is Dr. Jose Florez, Chief of the Endocrine Division and Diabetes Unit at the Massachusetts General Hospital.

Host: John Buse, MD, PhD Guest: Carolyn Bramante Emerging research has shed light on the possibility of generic drugs being repurposed for the treatment of COVID-19. Dr. John Buse discusses metformin, ivermectin, and fluvoxamine with Dr. Carolyn Bramante, an Assistant Professor in the Division of Geriatrics, Palliative and Primary Care at the University of Minnesota Medical School.

Host: John Buse, MD, PhD Guest: Ania Jastreboff, MD, PhD In the ongoing battle against obesity, what does the SURMOUNT-1 study tell us about the role of tirzepatide? Dr. Ania Jastreboff, who is an Associate Professor of Medicine and the co-director of Weight Management and Obesity Prevention Program at Yale School of Medicine, chats with Dr. John Buse and this study’s findings.

Host: John Buse, MD, PhD Guest: Rodica Pop-Busui, MD, PhD The American Diabetes Association (ADA) published a new consensus report with the American College of Cardiology on heart failure in patients with diabetes. What does this report recommend—and how will these recommendations impact clinical practice? Dr. John Buse speaks with Dr. Rodica Pop-Busui from the University of Michigan about these u...

Host: John Buse, MD, PhD Guest: Kenneth Cusi, MD, FACP, FACE The American Association of Clinical Endocrinology (AACE) released new recommendations for the diagnosis and management of NAFLD and NASH. To learn more about these updates, Dr. John Buse speaks with Dr. Kenneth Cusi, who is the Chief of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the Universit...

Host: John Buse, MD, PhD Guest: David Spence, MD Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Str...